Alkylation of opioid receptors by 5′-naltrindole-isothiocyanate injected into the nucleus accumbens of rats: Receptor selectivity and anatomical diffusion

Synapse

Volumn 60, Issue 5, 2006, Pages 384-391

  Martin, Thomas J ^a   McIntosh, Scot ^a   Smith, James E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

receptors; receptors; Antagonist; Brain; Central nervous system; Irreversible; Limbic system; Opioid

Indexed keywords

CHLORNALTREXAMINE; DELTA OPIATE RECEPTOR; DELTORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ISOTHIOCYANIC ACID; MU OPIATE RECEPTOR; NALTRINDOLE; OPIATE ANTAGONIST; OPIATE RECEPTOR; RECEPTOR SUBTYPE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DIFFUSION; LIMBIC SYSTEM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ALKYLATION; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ISOTHIOCYANATES; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NUCLEUS ACCUMBENS; OLIGOPEPTIDES; PHOSPHATIDYLETHANOLAMINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED F344; RECEPTORS, OPIOID, DELTA; TRANSFERASES;

EID: 33747056576     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20310     Document Type: Article

References (36)

1. Barrett AC, Smith ES, Picker MJ. 2003. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: Comparison of beta-funaltrexamine and clocinnamox. J Pharmacol Exp Ther 305:1061-1070.
2. Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JH, Woods JH, Traynor JR. 2000. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. J Pharmacol Exp Ther 294:933-940.
3. Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR. 2002. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 303:723-729.
4. Buzas B, Izenwasser S, Portoghese PS, Cox BM. 1994. Evidence for delta opioid receptor subtypes regulatin adenylyl cyclase activity in rat brain. Life Sci 54:PL101-PL106.
5. Chakrabarti S, Sultana M, Portoghese PS, Takemori AE. 1993. Differential antagonism by naltrindole-5′-isothiocyanate on [3H]DSLET and [3H]DPDPE binding to striatal slices of mice. Life Sci 53:1761-1765.
6. De Waele JP, Kiianmaa K, Gianoulakis C. 1995. Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats. J Pharmacol Exp Ther 275:518-527.
7. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. 1992. Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955.
8. Jiang Q, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI, Porreca F. 1991. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5′-isothiocyanate: Evidence for delta receptor subtypes. J Pharmacol Exp Ther 257:1069-1075.
9. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. 1992. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 89:12048-12052.
10. Kitchen I, Slowe SJ, Matthes HW, Kieffer B. 1997. Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res 778:73-88.
11. Martin TJ, Sim LJ, Selley DE, deMontis MG, Childers SR. 1997. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections. Synapse 27:177-182.
12. Martin TJ, DeMontis MG, Kim SA, Sizemore GM, Dworkin SI, Smith JE. 1998. Effects of beta-funaltrexamine on dose-effect curves for heroin self-administration in rats: Comparison with alteration of [3H]DAMGO binding to rat brain sections. Drug Alcohol Depend 52:135-147.
13. Martin TJ, Kim SA, Cannon DG, Sizemore GM, Bian D, Porreca F, Smith JE. 2000. Antagonism of delta(2)-opioid receptors by naltrindole-5′- isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294:975-982.
14. Martin TJ, Kim SA, Lyupina Y, Smith JE. 2002. Differential involvement of mu-opioid receptors in the rostral versus caudal nucleus accumbens in the reinforcing effects of heroin in rats: Evidence from focal injections of beta-funaltrexamine. Psychopharmacology (Berl) 161:152-159.
15. Mattia A, Farmer SC, Takemori AE, Sultana M, Portoghese PS, Mosberg HI, Bowen WD, Porreca F. 1992. Spinal opioid delta antinociception in the mouse: Mediation by a 5′-NTII-sensitive delta receptor subtype. J Pharmacol Exp Ther 260:518-525.
16. McLaughlin JP, Sebastian A, Archer S, Bidlack JM. 1997. 14 beta-Chlorocinnamoylamino derivatives of metopon: Long-term mu-opioid receptor antagonists. Eur J Pharmacol 320:121-129.
17. McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM. 1999. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: In vivo and in vitro characterization of mu-selective agonist and antagonist activity. J Pharmacol Exp Ther 289:304-311.
18. Mika J, Przewlocki R, Przewlocka B. 2001. The role of delta-opioid receptor subtypes in neuropathic pain. Eur J Pharmacol 415:31-37.
19. Olinias MC, Onali P. 1995. Participation of delta opioid receptor subtypes in the stimulation of adenylyl cyclase activity in rat olfactory bulb. J Pharmacol Exp Ther 275:1560-1567.
20. Parkhill AL, Bidlack JM. 2002. Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. Eur J Pharmacol 451:257-264.
21. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego, CA: Academic Press.
22. Porreca F, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI. 1992. Modulation of μ-mediated antinociception in the mouse involves opioid δ-2 receptors. J Pharmacol Exp Ther 263:147-152.
23. Portoghese PS, Sultana M, Takemori AE. 1990. Naltrindole 5′isothiocyanate: a nonequilibrium, highly selective delta opioid receptor antagonist. J Med Chem 33:1547-1548.
24. Ragnauth A, Moroz M, Bodnar RJ. 2000. Multiple opioid receptors mediate feeding elicited by mu and delta opioid receptor subtype agonists in the nucleus accumbens shell in rats. Brain Res 876:76-87.
25. Rawls SM, Hewson JM, Inan S, Cowan A. 2005. Brain delta2 opioid receptors mediate SNC-80 evoked hypothermia in rats. Brain Res 1049:61-69.
26. Rosin A, Kitchen I, Georgieva J. 2003. Effects of single and dual administration of cocaine and ethanol on opioid and ORL1 receptor expression in the rat CNS: An autoradiographic study. Brain Res 978:1-13.
27. Sanchez-Blazquez P, Rodriguez-Diaz M, Frejo MT, Garzon J. 1999. Stimulation of mu- and delta-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: Evidence for subtypes of delta-receptors. Eur J Neurosci 11:2059-2064.
28. Sufuoglu M, Portoghese PS, Takemori AE. 1993. 7-Benylidenenaltexone (BNTX): A selective delta 1 opioid receptor antagonist in the mouse spinal cord. Life Sci 52:769-775.
29. Suzuki T, Tsuji M, Mori T, Misawa M, Endoh T, Nagase H. 1995. Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice. Life Sci 57:155-168.
30. Suzuki T, Tsuji M, Mori T, Ikeda H, Misawa M, Nagase H. 1997. Involvement of dopamine-dependent and independent mechanisms in the rewarding effects mediated by delta opioid receptor subtypes in mice. Brain Res 744:327-334.
31. Tam L, Rafferty MF. 1994. Evidence for chemical differentiation of delta opioid receptor subtypes by the sulfhydryl reagent N-ethylmaleimide. Receptor 4:81-91.
32. Tseng LF, Narita M, Mizoguchi H, Kawai K, Mizusuna A, Kamei J, Suzuki T, Nagase H. 1997. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidergic delta opioid receptor agonist, (-) TAN-67, in the mouse spinal cord. J Pharmacol Exp Ther 280:600-605.
33. Vanderah T, Takemori AE, Sultana M, Portoghese PS, Mosberg HI, Hruby VJ, Haaseth RC, Matsunaga TO, Porreca F. 1994. Interaction of [D-Pen2,D-Pen5] enkephalin and [D-Ala2,Glu4]deltorphin with delta-opioid receptor subtypes in vivo. Eur J Pharmacol 252:133-137.
34. Walker EA, Young AM. 2002. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine. J Pharmacol Exp Ther 302:101-110.
35. Ward SJ, Portoghese PS, Takemori AE. 1982. Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. Eur J Pharmacol 80:377-384.
36. Ward SJ, Martin TJ, Roberts DC. 2003. Beta-funaltrexamine affects cocaine self-administration in rats responding on a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 75:301-307.